Clinical Trial Update: Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and pharmacokinetics of JCAR017 in B-cell non-Hodgkin lymphomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Mediastinal B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• JCAR017

Snippet

Sponsor: Juno Therapeutics, a Subsidiary of Celgene | Conditions: Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Status: COMPLETED